Onconetix (ONCO) currently reports a ROE of -75.7%. That is below the Healthcare sector average of 20.77%. Use the charts on this page to explore Onconetix's ROE history and peer comparisons.

Onconetix's ROE of -75.7% is lower than the Healthcare sector average of 20.77%. That is roughly 464.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Onconetix's current -75.7% should be judged against Healthcare norms (sector average: 20.77%) and against ONCO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -75.7%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 20.77%. From there, open related valuation or income-statement pages for Onconetix, and consider following ONCO for alerts when major investors trade the stock.

Onconetix is classified in the Healthcare sector. On ROE, it currently shows -75.7% versus a sector average near 20.77%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ONCO with unrelated industries.